Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(20):1518-1520; doi:10.1093/jnci/94.20.1518
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 20, 1518-1520, October 16, 2002
© 2002 Oxford University Press

NEWS

For Institutional Review Boards, Decisions Can Be Subjective

Tom Reynolds

The first 10% of the full text of this article appears below.

When evaluating a clinical trial protocol, institutional review boards (IRBs) must determine whether the likely benefits to patients outweigh the risks. How do IRBs sort through the complexity of medical, scientific, and ethical considerations to reach these decisions?

In a new study, researchers in the Netherlands interviewed 53 IRB members from six research hospitals and cancer centers to find out how they make risk/benefit assessments for phase II cancer clinical trials. The results suggest that they use a range of approaches but rarely employ a formal, systematic analysis. In an article published in the Aug. 1 Annals of Oncology, Heleen van Luijn, Ph.D., of the Institute for Ethics, Vrije Universiteit, Amsterdam, and colleagues describe findings from the first phase of a four-part study in which they . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
Resources
J Natl Cancer Inst, May 7, 2003; 95(9): 637 - 637.
[Full Text]